293 related articles for article (PubMed ID: 30043873)
21. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
[TBL] [Abstract][Full Text] [Related]
22. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
23. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
Nemoz B; Ternant D; Bailly S; Gautier-Veyret E; Jourdil JF; Bonaz B; Stanke-Labesque F
Br J Clin Pharmacol; 2019 Apr; 85(4):722-728. PubMed ID: 30575085
[TBL] [Abstract][Full Text] [Related]
24. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
25. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
26. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease.
Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934
[TBL] [Abstract][Full Text] [Related]
27. Antibody response to infliximab and its impact on pharmacokinetics can be transient.
Vande Casteele N; Gils A; Singh S; Ohrmund L; Hauenstein S; Rutgeerts P; Vermeire S
Am J Gastroenterol; 2013 Jun; 108(6):962-71. PubMed ID: 23419382
[TBL] [Abstract][Full Text] [Related]
28. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
Choi SY; Kang B; Lee JH; Choe YH
Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
[TBL] [Abstract][Full Text] [Related]
29. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
30. Infliximab levels and antibodies in IBD-related peripheral arthralgia.
Levartovsky A; Ungar B; Yavzori M; Picard O; Fudim E; Eliakim R; Paul S; Roblin X; Ben-Horin S; Kopylov U
Int J Colorectal Dis; 2020 Jun; 35(6):1141-1148. PubMed ID: 32296932
[TBL] [Abstract][Full Text] [Related]
31. Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®.
Marini JC; Sendecki J; Cornillie F; Popp JW; Black S; Blank M; Gils A; Van Stappen T; Hamann D; Rispens T; Thérien L; Chun K; Shankar G
AAPS J; 2017 Jan; 19(1):161-171. PubMed ID: 27600137
[TBL] [Abstract][Full Text] [Related]
32. Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
Liefferinckx C; Minsart C; Toubeau JF; Cremer A; Amininejad L; Quertinmont E; Devière J; Gils A; van Gossum A; Franchimont D
Inflamm Bowel Dis; 2017 Aug; 23(8):1371-1381. PubMed ID: 28498153
[TBL] [Abstract][Full Text] [Related]
33. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Lo Pumo S; Brunacci M; De Bortoli N; Jain A; Tolone S; Savarino E
Dig Liver Dis; 2018 May; 50(5):452-456. PubMed ID: 29274766
[TBL] [Abstract][Full Text] [Related]
34. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study.
Borren NZ; Paulides E; Frinack JL; Olson RN; Willrich MAV; van der Woude CJ; Ananthakrishnan AN
Dig Dis Sci; 2021 Oct; 66(10):3548-3554. PubMed ID: 33037969
[TBL] [Abstract][Full Text] [Related]
35. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
[TBL] [Abstract][Full Text] [Related]
36. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
37. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
J Crohns Colitis; 2018 Nov; 12(11):1316-1325. PubMed ID: 30239644
[TBL] [Abstract][Full Text] [Related]
38. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
[TBL] [Abstract][Full Text] [Related]
39. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.
Bjerrum JT; Steenholdt C; Ainsworth M; Nielsen OH; Reed MA; Atkins K; Günther UL; Hao F; Wang Y
BMC Med; 2017 Oct; 15(1):184. PubMed ID: 29032767
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
